Clobetasol

Evidence Level: L3

Predicted Indications: 1

Clobetasol

Pharmacist Assessment Report

Clobetasol: From Topical Corticosteroid-Responsive Skin Disease to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Clobetasol is a super-potent topical corticosteroid marketed in India as creams, ointments and a lotion; the data compiled for this report do not list a specific approved indication. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma, particularly early-stage mycosis fungoides. Support comes from 15 publications (including two observational cohort studies and a long-running clinical series) and no registered clinical trials.

Quick Overview

Item	Content
Original Indication	Not stated in the available India licence data (the approved-indication text is blank for all licences)
Predicted New Indication	Primary cutaneous T-cell lymphoma
TxGNN Prediction Score	0.9951
Evidence Level	L3
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on known pharmacology, clobetasol propionate is a super-potent topical glucocorticoid. Activating the glucocorticoid receptor can induce apoptosis in malignant T cells. It also dampens the inflammatory cytokine environment and the skin-homing T-cell infiltrate that drives patch- and plaque-stage mycosis fungoides, the most common primary cutaneous T-cell lymphoma.

Topical corticosteroids are already used as skin-directed therapy for early-stage disease (stage IA–IB). This is therefore an established off-label use rather than a speculative prediction, which is consistent with the very high TxGNN score.

The main limitation is that the effect is local. Clobetasol suits limited patch or thin-plaque disease, not tumour-stage, erythrodermic or systemic disease. Prolonged use of a super-potent steroid also carries risks of skin atrophy and suppression of the hypothalamic–pituitary–adrenal (HPA) axis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14686970	2003	Cohort / clinical series	Dermatol Ther	About 200 patch-stage MF patients treated with high-potency topical steroids at UCSF; response rate over 90%, minor side effects; topical clobetasol is first-line for early-stage MF there
32603400	2020	Cohort (observational)	Cutis	Evaluated cutaneous adverse effects of clobetasol propionate 0.05% cream in early-stage MF; superpotent steroids described as highly effective with minor side effects
39741016	2025	Cohort	An Bras Dermatol	Compared clobetasol propionate with bexarotene in early-stage MF
8987063	1996	Case series	Pediatr Dermatol	Weekly pulse superpotent topical steroid therapy was successful in three children with lymphomatoid papulosis
25027222	2014	Case report	Ned Tijdschr Geneeskd	Child with hypopigmented MF successfully treated with clobetasol 0.05% ointment 4 days a week
23773745	2013	Case report / review	Ann Dermatol Venereol	Report and literature review of papular MF, a newly described early form
36846176	2023	Case report / review	Clin Case Rep	MF with psoriasiform plaques, initially misdiagnosed as psoriasis and not responding to topical steroids
28031140	2016	Case report	Skinmed	Angioimmunoblastic T-cell lymphoma with skin presentation, initially treated as psoriasis with methotrexate and topical clobetasol; condition worsened

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
122219	Lobesol Cream	Tube of 15 gm cream	Not stated
34940	Clobet Cream	Tube of 15 gm cream	Not stated
39089	Clobaderm Ointment	Tube of 10 gm ointment	Not stated
27807	Becomed gm Cream	Tube of 10 gm cream	Not stated
35937	Clonext Cream	Tube of 30 gm cream	Not stated

There are 20 valid single-ingredient registrations in total; the table shows the first five. All are topical products (cream, ointment, lotion).

Safety Considerations

Drug Interactions: The database query found 175 potential interactions, but none has a severity grade. Examples include other corticosteroids (triamcinolone, prednisone, prednisolone, hydrocortisone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), calcitriol, doxycycline and morphine.
Class-related risks (from the mechanistic assessment): Prolonged use of a super-potent topical steroid risks skin atrophy and HPA-axis suppression. The observational literature on early-stage MF reports mostly minor side effects.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Observational cohort data and long-standing clinical practice support topical clobetasol as first-line skin-directed therapy for early-stage mycosis fungoides. No registered trials exist, and the evidence is limited to observational studies and case reports. Use should be restricted to limited patch or thin-plaque disease under dermatological supervision.

To proceed, the following is needed:

Package insert warnings and contraindications for the India products (currently a blocking data gap for safety screening)
Approved indication text for the registered products
Detailed mechanism of action data
Prospective or controlled data on efficacy, and defined limits on treatment duration and body surface area to manage skin atrophy and HPA-axis suppression
Confirmation that the available topical formulations suit the target lesions, and a plan for escalating to other therapy in tumour-stage or erythrodermic disease
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.